**Kiadis Pharma to present at upcoming investor conferences in**

**March 2019**

**Amsterdam, The Netherlands, March 1, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS)**, a clinical stage biopharmaceutical company, today announces that it is scheduled to present at the following investor conferences in March 2019.

Cowen Healthcare Conference

*March 11-13, 2019, Marriott Copley Place, Boston, MA, USA*

*Kiadis will be presenting on March 12th at 10:00 EST.*

[BioCapital Europe](https://www.biocapitaleurope.com/)

*March 14, 2019, Sofitel Legend Amsterdam The Grand, Amsterdam, Netherlands*

*Kiadis will be presenting at 17:00 CET.*

[Oppenheimer 29th Annual Healthcare Conference](https://www.opco.com/conferences/)

*March 19-20, 2019, The Westin New York Grand Central, New York, NY, USA*

*Kiadis will be presenting on March 19, 2019 at 14:45 EST.*

[KBC Securities Healthcare Conference](https://www.kbcsecurities.com/events/)

*March 27, 2019, Convene Grand Central, New York, NY, USA*

*Kiadis will be participating and hosting meetings with investors; there are no company presentations at this conference.*

***Kiadis Contacts:***

|  |  |
| --- | --- |
| **Kiadis Pharma**:Amy Sullivan, SVP, Corporate AffairsTel. +1 508 479 3480a.sullivan@kiadis.com | **Optimum Strategic Communications**:Mary Clark, Supriya Mathur, Hollie VileTel: +44 203 950 9144David Brilleslijper (Amsterdam)Tel: +31 610 942 514kiadis@optimumcomms.com |

**About Kiadis Pharma**

Kiadis Pharma is developing its lead product candidate, ATIR101, for use in conjunction with haploidentical HSCT for adult blood cancers to address key limitations of haploidentical HSCT, without prophylactic immunosuppression and its associated morbidity and mortality. Based on the positive results from the single dose Phase II CR-AIR-007 study, the Company submitted a marketing authorization application to the European Medicines Agency in April 2017 for approval of ATIR101 as an adjunctive treatment in haploidentical HSCT for high risk adult hematological malignancies. If the product is conditionally approved, Kiadis Pharma intends to launch ATIR101 in selected countries in Europe through its own commercial organization starting in the second half of 2019.

In December 2017, Kiadis Pharma commenced an international, multicenter, randomized and controlled Phase III clinical trial of ATIR101 against the Post-Transplant Cyclophosphamide, or PTCy protocol, the main protocol used to perform a haploidentical HSCT. The trial will be performed in 250 patients with acute leukemia and myelodysplastic syndrome at approximately 50 sites in the United States, Canada, Europe and certain additional countries. ATIR101 received regenerative medicine advanced therapy designation from the FDA in September 2017, which provides benefits that are materially equivalent to a breakthrough designation from the FDA. In addition, ATIR101 has been granted multiple orphan Drug designations both in the European Union and the United States.

The Company's shares are listed on Euronext Amsterdam and Brussels under the ticker KDS.

**Forward Looking Statements**

*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma's or, as appropriate, Kiadis Pharma's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*